Potential pathogenetic role of a novel ABCC8 missense variant on both transient neonatal diabetes mellitus and fetal growth restriction: a case report.
Case report
Fetal growth restriction
Hyperglycemia
Missense variant
Preterm infant
Transient neonatal diabetes mellitus
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
11
04
2024
accepted:
22
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
The diagnosis of neonatal diabetes can be problematic in preterm infants with fetal growth restriction (FGR). Growth restricted fetuses may have impaired insulin production and secretion; low birthweight infants may have a reduced response to insulin. We report a novel missense ABCC8 variant associated with a clinical phenotype compatible with transient neonatal diabetes mellitus (TNDM) in a fetal growth restricted preterm infant. A preterm growth restricted infant experienced hyperglycemia from the first day of life, requiring insulin therapy on the 13th and 15th day of life and leading to the diagnosis of TNDM. Glycemic values normalized from the 35th day of life onwards. Genetic screening was performed by next generation sequencing, using a Clinical Exon panel of 4800 genes, filtered for those associated with the clinical presentation and by means of methylation-specific multiplex ligation-dependent probe amplification analysis to identify chromosomal aberrations at 6q24. Genetic tests excluded defects at 6q24 and were negative for KCNJ11, SLC2A2 (GLUT-2) and HNF1B, but revealed the presence of the heterozygous missense variant c.2959T > C (p.Ser987Pro) in ABCC8 gene. The presence of the variant was excluded in parents' DNA and the proband variant was then considered de novo. In our infant, the persistence of hyperglycemia beyond 3 weeks of life led us to the diagnosis of TNDM and to hypothesize a possible genetic cause. The genetic variant we found could be, most likely, the main cause of both FGR and TNDM.
Sections du résumé
BACKGROUND
BACKGROUND
The diagnosis of neonatal diabetes can be problematic in preterm infants with fetal growth restriction (FGR). Growth restricted fetuses may have impaired insulin production and secretion; low birthweight infants may have a reduced response to insulin. We report a novel missense ABCC8 variant associated with a clinical phenotype compatible with transient neonatal diabetes mellitus (TNDM) in a fetal growth restricted preterm infant.
METHODS AND RESULTS
RESULTS
A preterm growth restricted infant experienced hyperglycemia from the first day of life, requiring insulin therapy on the 13th and 15th day of life and leading to the diagnosis of TNDM. Glycemic values normalized from the 35th day of life onwards. Genetic screening was performed by next generation sequencing, using a Clinical Exon panel of 4800 genes, filtered for those associated with the clinical presentation and by means of methylation-specific multiplex ligation-dependent probe amplification analysis to identify chromosomal aberrations at 6q24. Genetic tests excluded defects at 6q24 and were negative for KCNJ11, SLC2A2 (GLUT-2) and HNF1B, but revealed the presence of the heterozygous missense variant c.2959T > C (p.Ser987Pro) in ABCC8 gene. The presence of the variant was excluded in parents' DNA and the proband variant was then considered de novo.
CONCLUSIONS
CONCLUSIONS
In our infant, the persistence of hyperglycemia beyond 3 weeks of life led us to the diagnosis of TNDM and to hypothesize a possible genetic cause. The genetic variant we found could be, most likely, the main cause of both FGR and TNDM.
Identifiants
pubmed: 38874636
doi: 10.1007/s11033-024-09668-2
pii: 10.1007/s11033-024-09668-2
doi:
Substances chimiques
ABCC8 protein, human
0
Sulfonylurea Receptors
0
Insulin
0
Types de publication
Journal Article
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
753Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Greeley SAW, Polak M, Njølstad PR, Barbetti F, Williams R, Castano et al (2022) ISPAD Clinical Practice Consensus guidelines 2022: the diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 23:1188–1211
doi: 10.1111/pedi.13426
pubmed: 36537518
pmcid: 10107883
Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM (2020) New insights into KATP channel gene mutations and neonatal diabetes mellitus. Nat Rev Endocrinol 16:378–393
doi: 10.1038/s41574-020-0351-y
pubmed: 32376986
Edghill EL, Flanagan SE, Ellard S (2010) Permanent neonatal diabetes due to activating mutations in ABCC8 and KCNJ11. Rev Endocr Metab Disord 11:193–198
doi: 10.1007/s11154-010-9149-x
pubmed: 20922570
Van Assche FA, De Prins F, Aerts L, Verjans M (1977) The endocrine pancreas in small-for-dates infants. Br J Obstet Gynaecol 84:751–753
doi: 10.1111/j.1471-0528.1977.tb12486.x
pubmed: 336076
Boehmer BH, Limesand SW, Rozance PJ (2017) The impact of IUGR on pancreatic islet development and β-cell function. J Endocrinol 235:R63–R76
doi: 10.1530/JOE-17-0076
pubmed: 28808079
pmcid: 5808569
Darendeliler F (2019) IUGR: genetic influences, metabolic problems, environmental associations/triggers, current and future management. Best Pract Res Clin Endocrinol Metab 33:101260. https://doi.org/10.1016/j.beem.2019.01.001
doi: 10.1016/j.beem.2019.01.001
pubmed: 30709755
Kajantie E, Strang-Karlsson S, Hovi P, Wehkalampi K, Lahti J, Kaseva N et al (2015) Insulin sensitivity and secretory response in adults born preterm: the Helsinki Study of very low birth weight adults. J Clin Endocrinol Metab 100:244–250
doi: 10.1210/jc.2014-3184
pubmed: 25303493
Decaro MH, Vain NE (2011) Hyperglycaemia in preterm neonates: what to know, what to do. Early Hum Dev 87(Suppl 1):S19–S22
doi: 10.1016/j.earlhumdev.2011.01.005
pubmed: 21276670
Ogilvy-Stuart AL, Beardsall K (2010) Management of hyperglycaemia in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 95: F126–F131. https://doi.org/10.1136/adc.2008.154716
Besser RE, Flanagan SE, Mackay DG, Temple IK, Shepherd MH, Shields BM et al (2016) Prematurity and genetic testing for neonatal diabetes. Pediatrics 138. https://doi.org/10.1542/peds.2015-3926
Hughes AE, Hattersley AT, Flanagan SE, Freathy RM (2021) Two decades since the fetal insulin hypothesis: what have we learned from genetics? Diabetologia 64:717–726
doi: 10.1007/s00125-021-05386-7
pubmed: 33569631
pmcid: 7940336
De Franco E, Saint-Martin C, Brusgaard K, Knight Johnson AE, Aguilar-Bryan L, Bowman P E et al (2020) Update of variants identified in the pancreatic β-cell KATP channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes. Hum Mutat 41:884–905
doi: 10.1002/humu.23995
pubmed: 32027066
pmcid: 7187370
Bonfanti R, Iafusco D, Rabbone I, Diedenhofen G, Bizzarri C, Patera PI et al (2021) Differences between transient neonatal diabetes mellitus subtypes can guide diagnosis and therapy. Eur J Endocrinol 184:575–585
doi: 10.1530/EJE-20-1030
pubmed: 33606663
Gu HF (2017) Genetic, epigenetic and Biological effects of Zinc Transporter (SLC30A8) in type 1 and type 2 diabetes. Curr Diabetes Rev 13:132–140
doi: 10.2174/1573399812666151123104540
pubmed: 26593983